Therapeutic uses of peptide nucleic acids (PNA) in oncology

被引:1
作者
Zaffaroni, N [1 ]
Villa, R [1 ]
Folini, M [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy
来源
LETTERS IN PEPTIDE SCIENCE | 2003年 / 10卷 / 3-4期
关键词
bcl-2; cancer; cell-penetrating peptide; c-myc; hammerhead ribozyme; PNA; telomerase;
D O I
10.1007/BF02484564
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peptide nucleic acids (PNAs) are DNA mimics in which the sugar-phosphate backbone has been replaced by an uncharged backbone based on amino acids. Due to their ability to bind to complementary polynucleotides. PNAs have been successfully used to inhibit transcription and/or translation of genes able to confer a survival advantage to cancer cells, such as c-myc and bcl-2. PNAs targeted to the RNA template region of telomerase have also been used to inhibit the catalytic activity of this enzyme, which is responsible for the immortalized phenotype of a large majority of tumor cells. Because it is thought that naked PNAs are not taken up spontaneously by most cells. a number of delivery strategies have been developed including the use of so-called 'cell-penetrating peptides'. Chimeric molecules made by coupling PNAs with such peptides have been shown to accumulate inside tumor cells to an extent sufficient to guarantee the biological effect of PNAs. Overall. these results indicate that PNAs may be useful tools for target-directed anticancer therapeutic interventions.
引用
收藏
页码:287 / 296
页数:10
相关论文
共 51 条
[21]   Human telomerase contains evolutionarily conserved catalytic and structural subunits [J].
Harrington, L ;
Zhou, W ;
McPhail, T ;
Oulton, R ;
Yeung, DSK ;
Mar, V ;
Bass, MB ;
Robinson, MO .
GENES & DEVELOPMENT, 1997, 11 (23) :3109-3115
[22]   A mammalian telomerase-associated protein [J].
Harrington, L ;
McPhail, T ;
Mar, V ;
Zhou, W ;
Oulton, R ;
Bass, MB ;
Arruda, I ;
Robinson, MO .
SCIENCE, 1997, 275 (5302) :973-977
[23]   Noninvasive intracellular delivery of functional peptides and proteins [J].
Hawiger, J .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (01) :89-94
[24]   Chemosensitisation of malignant melanoma by BCL2 antisense therapy [J].
Jansen, B ;
Wacheck, V ;
Heere-Ress, E ;
Schlagbauer-Wadl, H ;
Hoeller, C ;
Lucas, T ;
Hoermann, M ;
Hollenstein, U ;
Wolff, K ;
Pehamberger, H .
LANCET, 2000, 356 (9243) :1728-1733
[25]   Antisense properties of duplex- and triplex-forming PNAs [J].
Knudsen, H ;
Nielsen, PE .
NUCLEIC ACIDS RESEARCH, 1996, 24 (03) :494-500
[26]   Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation [J].
Kondo, S ;
Tanaka, Y ;
Kondo, Y ;
Hitomi, M ;
Barnett, GH ;
Ishizaka, Y ;
Liu, J ;
Haqqi, T ;
Nishiyama, A ;
Villeponteau, B ;
Cowell, JK ;
Barna, BP .
FASEB JOURNAL, 1998, 12 (10) :801-811
[27]   Cell-penetrating peptides [J].
Lindgren, M ;
Hallbrink, M ;
Prochiantz, A ;
Langel, U .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (03) :99-103
[28]   Cellular uptake of adamantyl conjugated peptide nucleic acids [J].
Ljungstrom, T ;
Knudsen, H ;
Nielsen, PE .
BIOCONJUGATE CHEMISTRY, 1999, 10 (06) :965-972
[29]   Prospects for the therapeutic use of antigene oligonucleotides [J].
Maher, LJ .
CANCER INVESTIGATION, 1996, 14 (01) :66-82
[30]   2′-Carbohydrate modifications in antisense oligonucleotide therapy:: importance of conformation, configuration and conjugation [J].
Manoharan, M .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1489 (01) :117-130